Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689474 | 0.87 | RXRA (0.33) | PTAFRMAPT | |
| SCHEMBL5689619 | 0.87 | HEXA (0.38) | RAB9ASMN1; SMN2KIF11 | |
| SCHEMBL5689802 | 0.86 | TSHR (0.35) | PTAFRGRIA2GRIA4BRD4CREBBP | |
| SCHEMBL5691597 | 0.86 | TSHR (0.35) | PTAFRBRD4CREBBPTSHRNPC1 | |
| SCHEMBL6876306 | 0.84 | NR1H4 (0.32) | PTAFRGRIA2GRIA4BRD4CREBBP | |
| SCHEMBL28755373 | 0.84 | — | — | |
| SCHEMBL5688730 | 0.83 | PTAFR (0.31) | PTAFRBRD4CREBBPTSHRNPC1 | |
| SCHEMBL5689647 | 0.83 | PDCD1 (0.35) | RAB9ATP53SMN1; SMN2HPGD | |
| SCHEMBL7106420 | 0.82 | NPC1 (0.38) | PTAFRGRIA2GRIA4NPC1RAB9A | |
| SCHEMBL6230667 | 0.81 | HEXA (0.37) | RAB9ASMN1; SMN2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511755-B1 | TRANSITION METAL COMPOUNDS THEIR PREPARATION AND THEIR USE IN CATALYST SYSTEMS FOR THE POLYMERIZATION AND COPOLYMERIZATION OF OLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2006-03-08 | — | — | EP | disclosed |
| US-20050182266-A1 | Transition metal componds their preparation and their use in catalyst systems for the polymerization and copolymerization of olefins | BASELL POLYOLEFINE GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| EP-1511755-A1 | TRANSITION METAL COMPOUNDS THEIR PREPARATION AND THEIR USE IN CATALYST SYSTEMS FOR THE POLYMERIZATION AND COPOLYMERIZATION OF OLEFINS | Basell Polyolefine GmbH (DE) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003106470-A1 | TRANSITION METAL COMPOUNDS THEIR PREPARATION AND THEIR USE IN CATALYST SYSTEMS FOR THE POLYMERIZATION AND COPOLYMERIZATION OF OLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182266-A1 | Transition metal componds their preparation and their use in catalyst systems for the polymerization and copolymerization of olefins | YAP1, COX14, CYCS | PTAFR 2746/4885GRIA2 926/4885GRIA4 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.